Gholizadeh Y, Poyart C, Juvin M, Beretti J L, Croizé J, Berche P, Gaillard J L
Laboratoire de Microbiologie, Institut National de la Santé de la Recherche Médicale U 411, Faculté de Médecine Necker-Enfants Malades, Paris, France.
J Clin Microbiol. 1996 Jun;34(6):1391-5. doi: 10.1128/jcm.34.6.1391-1395.1996.
Amino-terminal fragments of listeriolysin O (LLO) of 240 and 411 residues (fragments LLO240 and LLO411, respectively) were expressed in Escherichia coli as fusion polypeptides with maltose-binding protein (MBP) with the aim of producing specific antigens for use in serological tests. In Western blots (immunoblots) with crude bacterial extracts of the fusion polypeptides, the reactivities of MBP-LLO240 and MBP-LLO411 with anti-LLO antibody (ALLO)- and anti-streptolysin O antibody (ASLO)-positive human sera were first compared with that of the entire LLO (LLO530) also fused to MBP (MBP-LLO530). Sixteen of 17 (94.1%) ALLO-positive samples reacting with MBP-LLO530 also reacted with MBP-LLO411, whereas this proportion dropped to 11 of 17 (64.7%) with MBP-LLO240. Alternatively, 18 of 19 (94.7%) ASLO-positive samples giving an interpretable result reacted with MBP-LLO530, whereas 1 of 19 (5.3%) of these samples reacted with MBP-LLO240 or MBP-LLO411. The fusion polypeptide MBP-LLO411 was purified by maltose affinity chromatography and was further evaluated as a diagnostic antigen in a Western blot assay. Twenty-one of 21 (100%) serum samples obtained from patients with listeriosis and found to be positive for ALLO by a reference dot blot test reacted with MBP-LLO411, whereas 1 of 20 (5%) ASLO-positive serum samples and 1 of 100 (1%) serum samples from healthy adults were reactive. Thus, a polypeptide limited to the 411 amino-terminal residues of LLO is a specific and sensitive antigen for the detection of ALLO.
将李斯特菌溶血素O(LLO)的240个和411个残基的氨基末端片段(分别为片段LLO240和LLO411)在大肠杆菌中作为与麦芽糖结合蛋白(MBP)的融合多肽进行表达,目的是生产用于血清学检测的特异性抗原。在用融合多肽的粗细菌提取物进行的蛋白质免疫印迹(免疫印迹)中,首先将MBP-LLO240和MBP-LLO411与抗LLO抗体(ALLO)和抗链球菌溶血素O抗体(ASLO)阳性的人血清的反应性与同样与MBP融合的完整LLO(LLO530)进行比较。17份与MBP-LLO530反应的ALLO阳性样本中有16份(94.1%)也与MBP-LLO411反应,而与MBP-LLO240反应的比例降至17份中的11份(64.7%)。另外,19份给出可解释结果的ASLO阳性样本中有18份(94.7%)与MBP-LLO530反应,而这些样本中有1份(5.3%)与MBP-LLO240或MBP-LLO411反应。融合多肽MBP-LLO411通过麦芽糖亲和层析进行纯化,并在蛋白质免疫印迹分析中作为诊断抗原进一步评估。从李斯特菌病患者获得的21份血清样本在参考斑点印迹试验中被发现ALLO呈阳性,其中21份(100%)与MBP-LLO411反应,而20份ASLO阳性血清样本中有1份(5%)以及100份健康成年人血清样本中有1份(1%)呈反应性。因此,限于LLO的411个氨基末端残基的多肽是检测ALLO的特异性和敏感性抗原。